Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung

NCT00137839 is registered in ClinicalTrials.gov with Pasi A. Janne, MD, PhD as lead sponsor.

NCT NCT00137839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00137839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung
Lead sponsor
Pasi A. Janne, MD, PhD
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
July 31, 2019
Enrollment
84 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, non-small cell lung cancer